Minimum structural requirements for inhibitors of the zinc finger protein TRAF6-Reference-Cited by-同舟云学术

Minimum structural requirements for inhibitors of the zinc finger protein TRAF6

Published:2019-08 Issue:16 Volume:29 Page:2162-2167
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Radwan Mohamed O.,Koga Ryoko,Hida Tomohiro,Ejima Tomohiko,Kanemaru Yosuke,Tateishi Hiroshi,Okamoto Yoshinari,Inoue Jun-ichiro,Fujita Mikako,Otsuka Masami

Funder

Institute of Medical Science

University of Tokyo

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference24 articles.

1. Zinc proteins: enzymes, storage proteins, transcription factors, and replication proteins;Coleman;Annu Rev Biochem,1992

2. Structure and stability of an unusual zinc-binding protein from Bacteroides thetaiotaomicron;Knaus;BBA,2014

3. The role of zinc in the stability of the marginally stable IscU scaffold protein;Iannuzzi;Protein Sci,2014

4. Zinc-binding site of human immunodeficiency virus 2 Vpx prevents instability and dysfunction of the protein;Yamamoto;J Gen Virol,2017

5. Introduction of H2C2-type zinc-binding residues into HIV-2 Vpr increases its expression level;Koga;FEBS Open Bio,2018

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ligand-based design and synthesis of new trityl histamine and trityl cysteamine derivatives as SIRT2 inhibitors for cancer therapy;European Journal of Medicinal Chemistry;2024-04

2. An ADAM17 selective inhibitor promotes glucose uptake by activating AMPK;Journal of Pharmacological Sciences;2024-01

3. Structural Characterization of TRAF6 N-Terminal for Therapeutic Uses and Computational Studies on New Derivatives;Pharmaceuticals;2023-11-14

4. Structural Characterization of TRAF6 N-terminal for Therapeutic Uses;2023-02-25

5. New Insights into the Structural Requirements of Isatin-Derived Pro-Apoptotic Agents against Acute Myeloid Leukemia;Pharmaceuticals;2022-12-17